No Data
No Data
KeyBanc Adjusts Price Target on AbCellera Biologics to $5 From $7, Maintains Overweight Rating
AbCellera Biologics (ABCL) has an average buy rating and price target range of $7 to $20, according to analysts polled by Capital IQ.Price: 2.90, Change: +0.10, Percent Change: +3.57
AbCellera Biologics Price Target Cut to $5.00/Share From $7.00 by Keybanc
AbCellera Biologics Price Target Cut to $5.00/Share From $7.00 by
KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Cuts Target Price to $5
KeyBanc analyst Scott Schoenhaus maintains $AbCellera Biologics(ABCL.US)$ with a buy rating, and adjusts the target price from $7 to $5.According to TipRanks data, the analyst has a success rate of 31
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
AdMare BioInnovations Expands With New Wet Laboratory Space in Vancouver
VANCOUVER, British Columbia--(BUSINESS WIRE)--#Ecosystems--adMare BioInnovations is delighted to announce the location of its new wet laboratory facility to support emerging life sciences companies in
TD Cowen Maintains AbCellera Biologics(ABCL.US) With Buy Rating
TD Cowen analyst Steven Mah maintains $AbCellera Biologics(ABCL.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 22.4% and a total average return of -17.5% over the